loader2
Partner With Us NRI

J B Chemicals & Pharmaceuticals Ltd share Price

Company details

2,062.80
2,078.95
1,342.20
2,223.90
6M Return 0.45%
1Y Return 32.12%
Mkt Cap.(Cr) 15,993.26
Volume 12,549
Div Yield 0.86%
OI
-
OI Chg %
-
Volume 12,549

Open Free Trading Account Online with ICICIDIRECT

J B Chemicals & Pharmaceuticals Ltd.

Q1FY22 Result Announced for J B Chemicals & Pharmaceuticals Ltd.

Financial Highlights:

  • For the first quarter ended 30th June 2021, the Company recorded revenue of Rs. 606 crores as compared to Rs. 522.3 crores, registering growth of 16 % over the corresponding quarter ended 30th June, 2020. EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 5 % to Rs. 163.7 crores as compared to Rs. 155.4 crores. EBITDA margin for the quarter was at 27 % as compared to 29.8 %. Profit after Tax was flat at Rs. 118.9 crores as compared to Rs. 119.4 crores.
  • The organization continues to perform well with revenue momentum continuing to remain strong
  • Highest ever quarterly revenue recorded during the first quarter of FY21, despite lockdowns in key markets and supply chain challenges
  • Domestic Formulations business records 39 % growth while the International business revenue was largely flat as compared to Q1 FY21
  • As per MAT June 2021 IQVIA data, Domestic Formulations maintains secular outperformance compared to industry growth rates, driven by strength in chronic segments and expanding prescriber coverage
  • Uncertainty in view of the second wave of COVID-19 impacted growth in certain geographies in the international market during the quarter
  • Gross Margin profile continues to remain healthy at 64 % aided by good product mix
  • EBITDA margin remains strong despite cost base returning to normal level of operations during Q1 FY 22

Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JBCPL said, “The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry. Our new GoTo-Market(GTM) model has been implemented and early signs are encouraging, which is reflected in the strong performance of flagship brands and new launches. While demand trends in international business continue to be volatile (given the COVID situation); our key markets like US, S Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival. We expect the performance to improve in select pockets of our international business. Going forward, our priority continues to build on cost efficiency measures while maintaining the same growth momentum”

 

Result PDF

View Other Company Results

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

J B Chemicals & Pharmaceuticals Ltd Stocks COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 2,134.13 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 943.10 30,847.85
LAST 3M 20,755.03 48,947.51
LAST 6M 63,750.52 33,855.80
LAST 12M 121,409.17 70,734.12
Board of J B Chemicals & Pharmaceuticals recommends final dividend

May 27, 2023 l BSE Announcement

JB Chemicals & Pharmaceuticals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

May 26, 2023 l NSE Announcement

JB Chemicals & Pharmaceuticals Limited - Investor Presentation

May 25, 2023 l NSE Announcement

Date Action Type Ratio
Feb 17, 2023 Dividend 425
Aug 12, 2022 Dividend 400
Feb 23, 2022 Dividend 425

J B Chemicals & Pharmaceuticals Ltd Information

Stock PE (TTM)
38.9
Promoter Holding
53.93%
Book Value
320.4361
ROCE
23.49%
ROE
18.68%
Description
  • JB Chemicals and Pharmaceuticals Ltd is a major player in the Indian pharmaceutical industry. It manufactures bulk drugs, chemicals, APIs, and a range of pharmaceutical products. It has five manufacturing facilities in Belapur, Thane, Ankleshwar, Panoli, and Daman. The majority of the company’s sales come from products such as Metrogyl, Rantac, and cardiac care medicines. The company also manufactures products for a wide range of therapeutic categories like gastroenterology, dermatology, hypertension, pharmacovigilance, and nicotine replacement therapy. Incorporated in 1976 in Maharashtra, JB Chemicals and Pharmaceuticals Ltd exports to 40 countries across the globe.

    The company is listed on the Bombay Stock Exchange with code 506943 and the National Stock Exchange with the symbol JBCHEPHARM. On November 22, 2022, JB Chemicals and Pharmaceuticals Ltd had a market capitalisation of Rs 16,131 crore.

    On November 22, 2022, JB Chemicals and Pharmaceuticals Ltd share price closed at Rs 2,043.95 per share, down by 2.01% from the open price of Rs 2,089.40. JB Chemicals and Pharmaceuticals Ltd’s share prices have increased by 430.04% over the past three years and 23.62% in the past 12 months. On November 22, 2022, the share’s 52-week high was Rs 2,150, and the 52-week low was Rs 1,342.20. 

    The company earned Rs 809 crore in revenue in the September 2022 quarter. It has been the best quarter of the year for the company. It made a profit of Rs 111 crore, which is 11% higher than its profit in the September 2021 quarter.

    Promoters hold 53.96% of the company’s shares, retail and others have a 19.31% stake, and 15.40% of the shares are held by mutual funds.

    Nikhil Chopra is the company’s CEO and the whole-time director, Dilip Singh Rathore is the president of India business, Kunal Khanna is the president of operations, Lakshay Kataria is the CFO, Bhushan Sachdev is the vice president of the supply chain department, and Bharat Dhanani is the vice president of operations.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code:  56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Neelam Centre 4th Floor, B-Wing Hind Cycle Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-2482 2222/2493 0918
Email : investorelations:jbcpl.com / secretarial:jbcpl.com
Website : http://www.jbpharma.com
Registrar

Datamatics Financial Services

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 506943
NSE Code : JBCHEPHARM
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE572A01028

FAQ’s on J B Chemicals & Pharmaceuticals Ltd Shares

You can buy J B Chemicals & Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy J B Chemicals & Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 29, 2023 10:19 AM the closing price of J B Chemicals & Pharmaceuticals Ltd was ₹ 2,066.90.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 29, 2023 10:19 AM, the market cap of J B Chemicals & Pharmaceuticals Ltd stood at ₹ 15,993.26.

The latest PE ratio of J B Chemicals & Pharmaceuticals Ltd as of May 29, 2023 10:19 AM is 38.9

The latest PB ratio of J B Chemicals & Pharmaceuticals Ltd as of May 29, 2023 10:19 AM is 0.16

The 52-week high of J B Chemicals & Pharmaceuticals Ltd is ₹ 2,223.90 while the 52-week low is ₹ 1,342.20

Download Our App

market app
market app